Endocrinol Metab > Volume 22(1); 2007 > Article
Journal of Korean Endocrine Society 2007;22(1):26-34.
DOI: https://doi.org/10.3803/jkes.2007.22.1.26    Published online February 1, 2007.
The Relationship between the Expression of MHC Class II Antigens and the Clinical Prognosis of Papillary Thyroid Carcinoma Patients.
Jun Chul Lee, Seul Young Kim, Yun Sun Choi, Youn Sun Bai, Yun Jeung Kim, Ihn Suk Lee, Ki Hyun Kwon, So Young Rha, Bon Jeong Ku, Young Kun Kim, Heung Kyu Ro, Shengjin Li, Jin Man Kim, Young Suk Jo, Minho Shong
1Department of Internal Medicine, Chungnam National University College of Medicine, Korea.
2Department of Pathology, Chungnam National University College of Medicine, Korea.
3Department of Internal Medicine, Eulji University Hospital, Korea.
Abstract
BACKGROUND
Papillary thyroid carcinoma is among the most curable cancers, but some patients are at high risk for recurrence or even death. MHC antigens are essential molecules for the pathogenesis of carcinoma and also the physiologic immune responses against tumor. However, there is no data about the relationship between the expression of MHC antigens and the clinical prognosis of papillary thyroid carcinoma patients. METHODS: We analyzed the relationship between the various prognostic factors and the MHC antigen expression by conducting a retrospective study of 215 patients, who had undergone thyroidectomy for papillary thyroid carcinoma between 1987 and 2003. RESULTS: The expressions of MHC class II antigens were more frequent in papillary thyroid carcinoma than in the other thyroid diseases. Yet there was no statistically significant relationship between most of the clinicopathological factors and the expression of MHC class II antigens in papillary thyroid carcinoma patients. Interestingly, an HLA-DR expression was found in 8 (30.8%) of the 26 patients in the recurrence group and in 13 (76.5%) of the 17 patients in the non-recurrence group, and HLA-DP/DQ immunoreactivity was positive in 10 (38.5%) cases of the recurrence group and in 14 (82.4%) cases of the non-recurrence group. CONCLUSION: Papillary thyroid carcinoma showed a more frequent expression of MHC Class II antigens. However, the recurred papillary thyroid carcinoma showed a tendency to downregulate the expression of MHC class II antigens. Hence, the molecular mechanism for the expression of MHC class II antigens might have a role in the recurrence of papillary thyroid carcinoma.
Key Words: Major histocompatibility complex, Papillary thyroid carcinoma, Recurrence


Editorial Office
101-2503, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-716-2428    Fax: +82-2-714-5103    E-mail: journal@endocrinology.or.kr                

Copyright © 2021 by Korean Endocrine Society. All rights reserved.

Developed in M2PI

Close layer
prev next